Is Urogen Pharma Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Urogen Pharma Ltd (URGN) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Urogen Pharma Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Urogen Pharma Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Urogen Pharma Ltd?

Muslim investors may consider investing in Urogen Pharma Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Urogen Pharma Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Urogen Pharma Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Urogen Pharma Ltd updated?

The Shariah compliance status of Urogen Pharma Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Urogen Pharma Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Urogen Pharma Ltd?

You can check the latest Shariah compliance status of Urogen Pharma Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

URGN Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 15, 2026

Report Source: 2026 1st Quarter Report

Urogen Pharma Ltd. Stock Analysis URGN

United States Health Care Small Cap Report: Q1, 2026

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Key Statistics of Urogen Pharma Ltd (URGN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$28.26$29.59

Today's Open

$29.26

Volume

944.07K

P/E Ratio (TTM)

52 Week Range

$3.42$32.37

Market Cap

1.16B

Avg. Volume

977.65K

Dividend Yield

Financial Metrics & Statements of Urogen Pharma Ltd (URGN)

FAQ's for Urogen Pharma Ltd (URGN)

According to Musaffa’s Shariah screening methodology, Urogen Pharma Ltd (URGN) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.